- About Us
- Patients, Families & Visitors
- Health Professionals
- Research & Training
- Ways to Give
|About Us||Patients, Families & Visitors||For Health Professionals||Careers||Research & Training||Ways to Give|
July 23, 2012
On July 20, the Honourable Leona Aglukkaq, Minister of Health, visited with researchers at Lawson Health Research Institute (Lawson) where she highlighted how Harper Government investments are helping strengthen healthcare across the country. Lawson is the research institute of London Health Sciences Centre (LHSC) and St. Joseph’s Health Care London. The Minister also toured research labs at LHSC’s Victoria Hospital.
“Our Government is proud to support the outstanding work of health researchers across Canada,” said Minister Aglukkaq. “Canadians expect us to play a leadership role in healthcare, and we are doing exactly that by investing in people who will help find new treatments for patients, make the health system more efficient, and help more Canadians avoid going to hospitals in the first place.”
There are more than 10,000 health research projects underway in Canada right now that receive Harper Government funding. Some recent initiatives announced include:
Minister Aglukkaq met with Pamela Zabel and Dr. Muriel Brackstone, two researchers at Lawson. With their colleagues and federal financial support Zabel and Brackstone’s work resulted in new ways for imaging breast cancer tumours that makes more efficient use of the medical isotope Technetium-99m.
While conserving the supply of Technetium 99-m, the product assists surgeons operating on breast cancer patients, allowing for less invasive surgery and fewer complications.
According to Dr. Brackstone, “Technetium is a radioactive product that has become critical in breast cancer and melanoma surgeries to look for cancer spread to lymph nodes. It is also used in a number of imaging tests for the detection of cancer spread to other parts of the body. We have been able to demonstrate that a new technetium product works as well if not better than the currently available one, without requiring filtration where 70-90% of the precious technetium is wasted.”
“Our specialized product was patented due to its optimal sizing formulation,” says Zabel. “Extensive testing has been done and clinical trial submissions have been authorized with Health Canada. A commercial manufacturer is now sought to bring this product to market. CIHR funding is critical to bringing new clinical agents to Canadian patients and assessing their clinical utility.”
Federal support for health research primarily flows through its health research investment agency – the Canadian Institutes of Health Research (CIHR). CIHR supports the best in peer-reviewed health research with the vision of creating a healthier future for Canadians.
“Canadian health researchers across all research disciplines and themes continue to have a significant impact on the country’s international scientific excellence and competitiveness,” said Dr. Alain Beaudet, President of CIHR. “At CIHR, we prize the many achievements and contributions our researchers make to resolving pressing health challenges and to improving the health outcomes of patients and supporting a robust and sustainable health care system.”
From left to right: Jim Koropatnick, Assistant Director, Lawson; Susan Truppe, MP London North Centre; Laurie Gould, Vice President Patient Centred Care, LHSC; Muriel Brackstone, Lawson Scientist; Pamela Zabel, Lawson Scientist; the Honorable Leona Aglukkaq, Federal Minister of Health; Morag Park, Scientific Director, Canadian Institutes of Health Research; Gillian Kernaghan, President and CEO, St.Joseph's Health Care London; Frank Prato, Assistant Director, Lawson